CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
Aerpio Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for ocular diseases and diabetic complications. Its lead candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is developing a bispecific antibody for wet age-related macular degeneration and diabetic macular edema. The company collaborates with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 and headquartered in Cincinnati, Ohio, Aerpio emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced development model.
Sirrus Technology, Inc. offers precision optical thin film interference filters for laser systems, telecommunications equipment, and biomedical instruments. The company was incorporated in 2007 and is based in Santa Rosa, California.
Aerpio Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for ocular diseases and diabetic complications. Its lead candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is developing a bispecific antibody for wet age-related macular degeneration and diabetic macular edema. The company collaborates with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 and headquartered in Cincinnati, Ohio, Aerpio emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced development model.
Aerpio Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for ocular diseases and diabetic complications. Its lead candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is developing a bispecific antibody for wet age-related macular degeneration and diabetic macular edema. The company collaborates with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 and headquartered in Cincinnati, Ohio, Aerpio emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced development model.
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for kidney diseases. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis. The company is also advancing vadadustat, an oral therapy in Phase III development aimed at treating anemia in patients with chronic kidney disease, both on dialysis and non-dialysis. Akebia has formed collaboration agreements with Otsuka Pharmaceutical for the development of vadadustat in various global markets and with Mitsubishi Tanabe Pharma for its development in Japan and other Asian regions. Additionally, the company has a research and licensing agreement with Janssen Pharmaceutica for compounds targeting hypoxia-inducible factors. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
Tolera Therapeutics Inc., founded under the scientific and medical direction of Maria Siemionow, M.D., Ph.D., D.Sc., is a spin-off of the Cleveland Clinic focused on bringing more specific, and safer therapies to market with competitive speed. The company’s technology stems from immune modulation and transplant research done at the Cleveland Clinic under the leadership of Dr. Siemionow, an internationally recognized leader in the fields of microsurgery and transplantation. In addition to her surgical skills, she has focused her research efforts on the development of therapies to promote life-long acceptance of organ and tissue transplants, while reducing or eliminating the need for chronic immunosuppression therapies and their dangerous side effects. In addition, Dr. Siemionow’s efforts have led to new discoveries in immune system modulation. She has authored and contributed to over 180 peer reviewed articles on transplantation, immune suppression and organ tolerance.
Aerpio Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for ocular diseases and diabetic complications. Its lead candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is developing a bispecific antibody for wet age-related macular degeneration and diabetic macular edema. The company collaborates with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 and headquartered in Cincinnati, Ohio, Aerpio emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced development model.
Juventas Therapeutics, Inc., a clinical stage biotechnology company, develops non-viral gene therapies that activate natural processes to repair the body. The company focuses on treatment of non-healing wounds in patients with advanced peripheral artery disease. It offers JVS-100, a non-viral gene therapy that expresses stromal cell-derived factor-1 or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a range of disease states. Juventas Therapeutics, Inc. was formerly known as AcelleRX Therapeutics, Inc. and changed its name to Juventas Therapeutics, Inc. in April 2009. The company was founded in 2007 and is based in Cleveland, Ohio.
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for kidney diseases. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis. The company is also advancing vadadustat, an oral therapy in Phase III development aimed at treating anemia in patients with chronic kidney disease, both on dialysis and non-dialysis. Akebia has formed collaboration agreements with Otsuka Pharmaceutical for the development of vadadustat in various global markets and with Mitsubishi Tanabe Pharma for its development in Japan and other Asian regions. Additionally, the company has a research and licensing agreement with Janssen Pharmaceutica for compounds targeting hypoxia-inducible factors. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
Celleration Inc. develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a noncontact and low frequency ultrasound solution delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.
Tolera Therapeutics Inc., founded under the scientific and medical direction of Maria Siemionow, M.D., Ph.D., D.Sc., is a spin-off of the Cleveland Clinic focused on bringing more specific, and safer therapies to market with competitive speed. The company’s technology stems from immune modulation and transplant research done at the Cleveland Clinic under the leadership of Dr. Siemionow, an internationally recognized leader in the fields of microsurgery and transplantation. In addition to her surgical skills, she has focused her research efforts on the development of therapies to promote life-long acceptance of organ and tissue transplants, while reducing or eliminating the need for chronic immunosuppression therapies and their dangerous side effects. In addition, Dr. Siemionow’s efforts have led to new discoveries in immune system modulation. She has authored and contributed to over 180 peer reviewed articles on transplantation, immune suppression and organ tolerance.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for kidney diseases. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis. The company is also advancing vadadustat, an oral therapy in Phase III development aimed at treating anemia in patients with chronic kidney disease, both on dialysis and non-dialysis. Akebia has formed collaboration agreements with Otsuka Pharmaceutical for the development of vadadustat in various global markets and with Mitsubishi Tanabe Pharma for its development in Japan and other Asian regions. Additionally, the company has a research and licensing agreement with Janssen Pharmaceutica for compounds targeting hypoxia-inducible factors. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
Juventas Therapeutics, Inc., a clinical stage biotechnology company, develops non-viral gene therapies that activate natural processes to repair the body. The company focuses on treatment of non-healing wounds in patients with advanced peripheral artery disease. It offers JVS-100, a non-viral gene therapy that expresses stromal cell-derived factor-1 or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a range of disease states. Juventas Therapeutics, Inc. was formerly known as AcelleRX Therapeutics, Inc. and changed its name to Juventas Therapeutics, Inc. in April 2009. The company was founded in 2007 and is based in Cleveland, Ohio.
Celleration Inc. develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a noncontact and low frequency ultrasound solution delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
Tolera Therapeutics Inc., founded under the scientific and medical direction of Maria Siemionow, M.D., Ph.D., D.Sc., is a spin-off of the Cleveland Clinic focused on bringing more specific, and safer therapies to market with competitive speed. The company’s technology stems from immune modulation and transplant research done at the Cleveland Clinic under the leadership of Dr. Siemionow, an internationally recognized leader in the fields of microsurgery and transplantation. In addition to her surgical skills, she has focused her research efforts on the development of therapies to promote life-long acceptance of organ and tissue transplants, while reducing or eliminating the need for chronic immunosuppression therapies and their dangerous side effects. In addition, Dr. Siemionow’s efforts have led to new discoveries in immune system modulation. She has authored and contributed to over 180 peer reviewed articles on transplantation, immune suppression and organ tolerance.
CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.
HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
Sirrus Technology, Inc. offers precision optical thin film interference filters for laser systems, telecommunications equipment, and biomedical instruments. The company was incorporated in 2007 and is based in Santa Rosa, California.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.
HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
Kereos, Inc. is a biopharmaceutical company based in Saint Louis, Missouri, specializing in the development of targeted molecular imaging agents and therapeutics aimed at detecting and treating cancer and cardiovascular diseases. Established in 1999, Kereos utilizes a nanoscale drug delivery technology that enhances the targeting and efficacy of various therapeutic compounds, including existing drugs, new candidates, and those that may be too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001, a cancer therapeutic that combines paclitaxel with a targeted nanodroplet, KER-1002, which integrates a natural anti-tumor agent, and KER-1003, known for its anti-angiogenic properties. Additionally, Kereos offers diagnostic solutions such as KER 0001, designed to detect angiogenesis. The company also collaborates with pharmaceutical and imaging firms to further develop its MRI agents and targeted chemotherapeutics for solid tumors and cardiovascular applications.
Renal Solutions is focused on the development of dialysis products and services. Renal Solutions was acquired by Fresenius Medical Care in November 2007. Renal Solutions was founded in 2000 and is based in Warrendale, Pennsylvania.
Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. The company has developed innovative products, including RemonCHF, a device designed to monitor the hemodynamic status of patients with congestive heart failure, and RemonAAA, which tracks pressure following endograft procedures in patients with abdominal aortic aneurysms. By focusing on miniature implants and advanced medical devices, Remon Medical Technologies aims to enhance patient monitoring and care in critical health conditions.